---
title: Hypokalemia
author: J. Austin Straley, DO
category: mcspages
layout: post
lesson: 2.5.2.4
date: 2022-11-26
---

<html>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link href="{{site.baseurl}}/assets/grid/bootstrap-grid.min.css" rel="stylesheet">
    <link href="{{site.baseurl}}/assets/grid/grid.css" rel="stylesheet">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/gitbook-plugin-fontsettings/website.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/gitbook-plugin-search-pro/search.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/gitbook-plugin-back-to-top-button/plugin.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/style.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/custom.css">
    <link rel="stylesheet" href="{{site.baseurl}}/assets/gitbook/rouge/{{ site.syntax_highlighter_style | default: 'colorful' }}.css">
    <meta name="HandheldFriendly" content="true"/>
    <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <meta name="apple-mobile-web-app-status-bar-style" content="black">
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="{{site.baseurl}}/assets/gitbook/images/apple-touch-icon-precomposed-152.png">
    <link rel="shortcut icon" href="{{site.baseurl}}/{{site.favicon_path}}" type="image/x-icon">
    <style>
        .p {
            color: #B8B8B8;
        }
        .p1 {
            color
        }
    </style>
</html>

### Hypokalemia

-	General
    -	Most clinically affects the muscles/heart
    -	K+ is readily absorbed, thus false hypokalemia is possible with large numbers of metabolically active cells
        -	In hypokalemia, the kidneys should respond by secreting <20-25 mEq/day
    -	Pseudohypokalemia
        -	Insulin Excess
        -	Epinephrine
-	Main causes: 
    -	GI losses (Non-Renal) or Urinary losses (Renal) > Intracellular Shifting (insulin or beta-2 agonists (Albuterol), prednisone) > Decreased Intake
    -	Meds: Terbutaline, Epinephrine, Piperacillin
    -	Hypothermia
    -	Alkalemia
    -	Hypokalemic Periodic Paralysis
        -	1) Familial, onset <20 y/o
        -	2) Acquired in hyperthyroidism, Asian/Mexican Men
    -	A) GI losses
        -	Vomiting
        -	Diarrhea (most rapid)
            -	May see hypokalemia and hypomagnesemia
            -	Typically with metabolic acidosis
            -	May not normalize with potassium supplementation
            -	Worsened by laxatives or enemas
        -	Laxative abuse
            -	NAGMA or metabolic Alkalosis
        -	Gastroenteritis
            -	Not refractory to potassium supplements
        -	Tube drainage
        -	Inability to absorb
    -	B) Renal Losses
        -	AKD/CKD
        -	Hyperaldosteronism (aldosterone promotes excretion)
            -	Hypertension and metabolic alkalosis
        -	Uremia
        -	DKA (Osmotic Diuresis)
        -	Bicarb administration
        -	Hypomagnesemia
        -	Diuretic Abuse (Thiazide or Loop Diuretics)
            -	MCly seen with carbonic Anhydrase Inhibitors, loop diuretics, and thiazides
            -	Monitor in Athletes, or in 2 weeks after dose increase
        -	Bartter Syndrome, Gitelman Syndrome, Liddle Syndrome
        -	Hypokalemia + NAGMA
            -	RTA Type 1 and 2
    -	NSAIDs, Lithium, Foscarnet
    -	Acetazolamide, Topiramate, Aminoglycosides, Tenofovir, Valproic Acid, Chemo
    -	C) Intracellular Shifting
        -	Medication Induced
            -	MCly due to insulin, most typically seen after initial administration of insulin in a patient with DKA (give K+ if <3.3 + DKA prior to insulin)
            -	Alkalemia: H+ is pushed out of cells to correct alkalemia while K+ is pushed in
            -	B2 Activation: activation pushes K+ into cells
        -	Total body potassium is normal and potassium replacement may cause rebound hyperkalemia
        -	0.5 mEq/L or more change
    -	Refractory Hypokalemia + Alcoholic
        -	Hypomagnesemia inhibits PTH release (Hypocalcemia too)
            -	(Magnesium <1.6)
        -	Decreased intracellular magnesium leads to excess potassium efflux from renal tubular cells into the lumen (renal potassium wasting)
    -	May occur after B12 or folate replacement due to increased cell production
-	Symptoms: 
    -	Mild: fatigue, myalgias, weakness, cramps, constipation
    -	Moderate: Ileus
    -	Severe: Cramps, Flaccid paralysis with hyporeflexia, hypoventilation
    -	Cardiac arrhythmias (ST depression, T wave flattening, U waves, QT prolongation, Ventricular arrhythmias, Arrest)
    -	Glucose intolerance
    -	Renal impairment (rhabdomyolysis)
-	W/U: 
    -	Potassium, Calcium, Magnesium, Urine K, Urine and Serum Osm
    -	1) Urine and Serum K and Osmolality
        -	No longer recommended
        -	TTKG (Transtubular potassium gradient) is calculated with
        -	= (Urine K/Serum K)/ (Urine osm/Serum osm)
            -	TTKG <2 suggests non-renal source
            -	TTKG >4 suggests it is the result of inappropriate renal secretion of K+
    -	2) Urine K+
        -	<20 mEq/L: Extrarenal K+ Loss
            -	Get ABG
                -	Normal
                    -	Decreased K+ Intake (rare)
                    -	Laxative Abuse
                    -	Copious perspiration
                -	Metabolic Acidosis
                    -	GI Tract
                    -	Diarrhea
                    -	Villous Adenoma
                    -	Fistula
        -	>20 mEq/L: Renal K+ Loss
            -	Get ABG
                -	Metabolic Acidosis
                    -	RTA
                    -	Carbonic Anhydrases
                    -	DKA
                    -	Ureterosigmoidostomy
                -	Metabolic Alkalosis (Redistribution)
        -	Other) FeK
            -	<9.3%, Urine K+ < 13
                -	Diarrhea, Transcellular shift, lack of intake
            -	>9.3%, Urine K+ â‰¥13 (81% sensitive, 86% specific for renal wasting)
                -	Hypertensive: Aldosterone effect
                -	Not
                    -	Bicarb low: RTA
                    -	Bicarb not low:
                        -	Urine Na/Cl >1.6 or chloride <10: Emesis/Piperacillin
                        -	Urine Na/Cl 1 or chloride >20: Loops/Thiazides or genetic
-	Treatment
    -	Targets: 3.5-4.5 in most, >3 in renal failure, >5 in DKA with decent kidneys
    -	CI to enteral K+: Severe, profound shock, NPO
    -	Mild (3.0-3.5):
    -	Moderate (2.5-2.9):
    -	Severe (<2.5):
    -	Oral > IV Potassium replacement
    -	For every 10mEq of KCL given, serum K+ should rise by 0.1mEq/L
        -	Give with saline, not dextrose (drives K+ into cells via insulin secretion)
        -	KCL for metabolic alkalosis
        -	KHCO3 or K citrate/acetate for metabolic acidosis (NAGMA)
    -	IV KCL at a max of 20 mEq/hr via a central line if severe or worse
        -	Two infusions of 10mEq/hr in two peripherals if no central
    -	Treat concurrent hypomagnesemia
    -	Cardiac Arrest/VT/VF
        -	20mEq IV over 2-3 minutes
    -	Initiate PPI +/- Amiloride
